Patricia Inácio, PhD, science writer —

LisCure Biosciences is teaming up with Celltrion to identify and develop oral therapies targeting the gut microbiome — the population of microorganisms living in the gastrointestinal tract —for people with Parkinson’s disease, the company announced. Under the collaboration, the South Korean companies aim to develop orally available live biotherapeutic…

IntelGenx has teamed up with a renowned neurologist at the Karolinska Institute, Sweden to conduct a clinical trial on Montelukast VersaFilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The multicenter trial, expected to start between July and September, will be led by Per Svenningsson,…

Mindfulness meditation — a mental training of being focused on the present moment without interpretation or judgment — was better than physical exercise at lessening depression symptoms and maintaining emotional stability in people with mild-to-moderate Parkinson’s disease. That’s according to data from a small clinical trial conducted in Hong…

Increasing doses of KM-819, a potential therapy being developed by Fascinate Therapeutics for Parkinson’s disease, showed a favorable safety profile in healthy older adults, according to data from the now-completed Part 1a of a Phase 2 trial. The placebo-controlled trial (NCT05670782), which was launched last year, is…

FGF-1, Zhittya Genesis Medical’s treatment candidate, appeared safe and effective at improving motor and cognitive function in  the first Parkinson’s disease patients given the therapy in an early clinical trial and followed for six months. That’s according to a press release from the company that also announced a…

Both type 2 diabetes and prediabetes — a condition in which blood sugar levels are abnormally high, but not high enough to constitute diabetes — are significantly associated with poorer cognition in people with Parkinson’s disease, according to a small study from South Korea. These findings add to previous…

Among people undergoing surgery to remove a damaged spinal disc in the neck, those with Parkinson’s disease had significantly longer in-hospital stays and a greater risk of minor adverse events, according to an analysis of data collected from the U.S. National Inpatient Sample database. No differences were seen, however,…

Changes in the structure of 76 proteins in the cerebrospinal fluid (CSF) of people with Parkinson’s disease were seen when compared with those of healthy individuals, a study reported. Its researchers believe their work is the first to look at protein structure — rather than abundance — to identify potential…

Metabolon is teaming up with Tracking Parkinson’s, the world’s largest long-term study into Parkinson’s disease, to identify novel metabolic biomarkers of disease progression. The discoveries may lead to personalized treatments and better patient care. “We are extremely enthusiastic about partnering with Tracking Parkinson’s to further the understanding…

Highland Instruments will use its new technology — called the Integrated Motion Analysis Suite or IMAS — to objectively improve the evaluation of motor function in Parkinson’s disease patients undergoing treatment with its novel noninvasive brain stimulation device, called Electrosonic Stimulation (ESStim). IMAS will now be included in an…